- Home
- MEHA vs RDHL Comparison
MEHA vs RDHL Comparison
Compare MEHA & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$0.39
HOLD
Current Price
$1.19
Company Overview
Basic Information| Metric | MEHA | RDHL |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 3.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MEHA | RDHL |
|---|---|---|
| Price | $0.39 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 68.5K |
| Earning Date | 01-01-0001 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,498,798.00 | ★ $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 157.62 |
| 52 Week Low | $0.33 | $1.01 |
| 52 Week High | $8.00 | $7.44 |
Technical Indicators
Market Signals| Indicator | MEHA | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 49.36 |
| Support Level | N/A | $1.18 |
| Resistance Level | N/A | $1.26 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 78.00 |
Price Performance
Historical Comparison MEHA
RDHL
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.